Johnson & Johnson: Carcinoma, Non-Small-Cell Lung trials

The registry lists 33 Carcinoma, Non-Small-Cell Lung studies with Johnson & Johnson as lead sponsor. 7 are open to participants now and 12 have results posted.

Phase 1 11Phase 2 13Phase 3 4No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)Not yet recruitingNCT07680907
• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCRecruitingNCT07586202Phase 2
• A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World SettingRecruitingNCT07230691
• A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung CancerRecruitingNCT07227025Phase 1/2
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06667908Phase 2
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06667076Phase 2
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT05498428Phase 2
• Premedication to Reduce Amivantamab Associated Infusion Related ReactionsActive, not recruitingNCT05663866Phase 2Results posted
• A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05388669Phase 3Results posted
• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureActive, not recruitingNCT04988295Phase 3Results posted
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsActive, not recruitingNCT04538664Phase 3Results posted
• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04487080Phase 3Results posted
• A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04075396Phase 1/2Results posted
• NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the LungTerminatedNCT03603652Not applicableResults posted
• A Prospective, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracoscopic LobectomiesCompletedNCT03056300Not applicableResults posted
• A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT03023423Phase 1/2Results posted
• Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) LobectomiesCompletedNCT02702921Not applicableResults posted
• Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in KoreaCompletedNCT02196675Results posted
• Powered Echelon Device in VATS SurgeryCompletedNCT01843192Results posted
• A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung CancerCompletedNCT06532032Phase 1/2
• Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibActive, not recruitingNCT06120140Phase 2
• A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung CancerActive, not recruitingNCT06116786Phase 1
• A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05908734Phase 1/2
• A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05488314Phase 1/2
• A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung CancerCompletedNCT04951154
• Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerApproved for marketingNCT04599712
• A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04077463Phase 1
• First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C MutationCompletedNCT04006301Phase 1
• NEUWAVE Flexible Probe Study #2WithdrawnNCT03713099Not applicable
• A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaCompletedNCT02699606Phase 2
• Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerActive, not recruitingNCT02609776Phase 1
• Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung CancerTerminatedNCT02592967Phase 1
• Powered Surgical Stapler in VATS Lung Resection Procedures in ChinaCompletedNCT02338583